A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours.
This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to (177)Lu-DOTATATE and with lower abdominal uptake than (131)I-TATE. In addition, (131)I-DOTATATE showed significative tumour uptake, despite not so persistent after 24h. (131)I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy.
de Araújo
E B
EB
Radiopharmacy Directory, Nuclear and Energetic Research Institute (IPEN), Av. Lineu Prestes, 2242, Cidade Universitária, Butantã, CEP 05508-000, São Paulo, Brazil. ebaraujo@ipen.br
Caldeira Filho
J S
JS
Nagamati
L T
LT
Muramoto
E
E
Colturato
M T
MT
Couto
R M
RM
Pujatti
P B
PB
Mengatti
J
J
Silva
C P G
CP
D000818:Animals; D002614:Chelating Agents; D006573:Heterocyclic Compounds, 1-Ring; D007457:Iodine Radioisotopes; D008187:Lutetium; D051379:Mice; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D010599:Pharmacokinetics; D011868:Radioisotopes; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014018:Tissue Distribution
D002614:Chelating Agents; D006573:Heterocyclic Compounds, 1-Ring; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; D013004:Somatostatin; D008187:Lutetium